Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Davis R M Inc.

Key Points

• Davis R M Inc. significantly increased its stake in Intuitive Surgical by 289.9% during the first quarter, now holding 5,879 shares valued at approximately $2.9 million.
• Institutional investors own 83.64% of Intuitive Surgical's stock, with major increases from firms like GAMMA Investing LLC, which raised its holdings by an extraordinary 54,010.7%.
• Intuitive Surgical reported an earnings per share (EPS) of $2.19 for the most recent quarter, surpassing analysts' expectations of $1.93 and marking a 21.4% increase in revenue year-over-year.

Davis R M Inc. grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 289.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,879 shares of the medical equipment provider's stock after acquiring an additional 4,371 shares during the quarter. Davis R M Inc.'s holdings in Intuitive Surgical were worth $2,912,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Chilton Capital Management LLC boosted its position in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the last quarter. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at approximately $26,000. Global Financial Private Client LLC raised its holdings in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. bought a new stake in Intuitive Surgical in the first quarter worth $26,000. Finally, Hurley Capital LLC bought a new stake in Intuitive Surgical in the fourth quarter worth $28,000. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary S. Guthart sold 7,893 shares of Intuitive Surgical stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $498.64, for a total value of $3,935,765.52. Following the completion of the transaction, the insider owned 13,187 shares in the company, valued at $6,575,565.68. This trade represents a 37.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,903 shares of company stock worth $7,932,778 over the last quarter. Insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 0.4%

Shares of Intuitive Surgical stock traded up $2.03 during trading on Friday, hitting $483.12. 2,982,876 shares of the stock traded hands, compared to its average volume of 1,997,437. The firm has a market cap of $173.19 billion, a P/E ratio of 67.38, a price-to-earnings-growth ratio of 5.04 and a beta of 1.60. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The stock's fifty day simple moving average is $524.01 and its 200 day simple moving average is $533.35.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.78 earnings per share. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ISRG shares. Wells Fargo & Company raised their price target on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Royal Bank Of Canada raised their price target on Intuitive Surgical from $605.00 to $615.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Citigroup restated a "buy" rating and issued a $650.00 price target (up from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Finally, UBS Group raised their price target on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus price target of $592.05.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.